Cookies used for improved website experience

Siemens Healthineers and our partners use cookies and other similar technologies to operate the Siemens Healthineers websites and personalize content and ads. You may find out more about how we use cookies by clicking "Show details" or by referring to our Cookie Policy.
You may allow all cookies or select them individually. And you may change your consent and cookie preferences anytime by clicking on the "Review and change your consent" button on the Cookie Policy page.

Evaluation of the Enhanced Atellica® IM SARS-CoV-2 IgG (sCOVG) Assay White Paper 

Demonstrates strong relationship between the Atellica IM sCOVG Assay index value and neutralization titer

01.04.21
Whitepaper Evaluation of the Enhanced Atellica® IM SARS-CoV-2 IgG(sCOVG) Assay White Paper

The enhanced Atellica® IM SARS-CoV-2 IgG (sCOVG)* Assay demonstrates analytical performance capable of measuring patient IgG antibody response to the S1 RBD antigen with accuracy and precision and is acceptable for quantifying an individual’s immune response, including production of neutralizing antibodies, and identifying an individual’s immunocompetence to the SARS-CoV-2 virus.

Learn more about the sCOVG assay performance.